Biotech Stock Alert: ACTU Gets Bullish Rerating with 318% Upside

HC Wainwright just doubled down on Actuate Therapeutics (ACTU), maintaining a Buy rating and signaling serious conviction here.

The numbers are wild:

• Average price target sits at $25.50/share — that’s a 318% jump from current levels at $6.10
• Analyst forecasts range from $20.20 to $36.75 (pretty tight consensus for a biotech play)
• Projected annual non-GAAP EPS: -$1.22 (so still in cash-burn mode)

Institutional interest is heating up:

• Fund positions jumped 74.51% last quarter, with 89 funds now holding positions
• Total institutional ownership increased 3.11% to 11.59M shares
• Average fund allocation to ACTU rose 48.49%

Who’s moving the dial?

• BIOS Capital Management holds 43.24% (10.05M shares) — a slight 0.84% increase
• Vanguard’s Total Stock Market Index Fund went wild: 97.74% position increase, portfolio allocation up 3,457% (that’s index rebalancing mechanics at work)
• Geode Capital added 18.82% more shares but paradoxically cut portfolio weighting

The takeaway: Analysts see significant upside, and smart money is quietly accumulating. But ACTU’s still unprofitable — this is a bet on pipeline execution, not current earnings. The divergence between share buying and portfolio weighting cuts tells you institutional holders are being selective.